NEUVÉ Health Review: Eleven Peptide Protocols, and a Pharmacy Certification That Does Not Exist

Phase 2 only

What the trials show for GHK-Cu

• NCT07437586 — Phase 2, recruiting, n=60. Acute skin wound healing, recruiting. The completed GHK-Cu registry record is a 27-participant phase 4 study of facial skin quality, hydration and barrier function.

Six words, and every one of them is inside the evidence. GHK-Cu's human record is about skin, the completed study measured facial skin quality and barrier function, and this product is a topical rather than an injection — so the route matches the literature too. It claims nothing about hair, which is the word almost every other seller of this molecule adds and none can support. This is what a defensible peptide claim looks like.¹

No trial for this use

What the trials show for Sermorelin

As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery or body composition as an outcome in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.

The first two words are the strongest peptide claim on this menu and the rest is not tested. Sermorelin raises growth hormone — 19 randomized trials measured exactly that. Recovery and body composition were an outcome in none of them, in healthy adults or anyone else, and the interpunct between the two halves of this claim does not tell a reader that one is evidence and one is hope.²

No trial for this use

As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.

Cellular energy and cognition are the two outcomes an injected NAD+ trial would have to measure, and no such trial has reported. The oral-precursor literature people reach for is about different molecules taken a different way. NEUVÉ puts this first in its list of what a patient may be prescribed.³

No trial for this use

What the trials show for Glutathione

As of August 2026, a PubMed search for glutathione in title or abstract, combined with an injected route and with skin, detoxification, fatigue or energy, restricted to the randomized-controlled-trial publication type, returned seven records. Not one tests injected glutathione on its own for any of those outcomes. On ClinicalTrials.gov, 268 studies list glutathione as an intervention; restricting to injected routes returns three, in mantle-cell lymphoma, acute liver failure and pneumonia.

"Detoxification" is not an outcome any trial of injected glutathione has measured, and the searches that would find one return seven records of which none tests the drug on its own. Glutathione is genuinely an antioxidant inside a cell — that is biochemistry rather than a clinical finding, and it is not the same as an injection producing an effect a patient would notice.⁴

Phase 1 only

• NCT02637284 — Phase 1, unknown status, n=42. The BPC-157 registry record in humans — phase 1, tolerability rather than effect, and its status is unknown rather than completed.
• NCT07487363 — Phase 1/Phase 2, recruiting, n=80. The TB-500 record, recruiting. No completed human efficacy result exists for either molecule in this blend.

Both molecules in this vial sit at phase 1, one with a status the registry lists as unknown and one still recruiting. Phase 1 asks whether a dose is tolerated; injury, inflammation and recovery time are effects, and no completed trial has measured any of them for either peptide. Naming athletes in the claim does not change what was tested — it names who is being sold to.^5,6

Phase 2 only

• NCT07437586 — Phase 2, recruiting, n=60. The GHK-Cu wound-healing record, recruiting — and studying a topical application rather than an injection.
• NCT02637284 — Phase 1, unknown status, n=42. BPC-157, phase 1, status unknown.

One of the three ingredients has skin evidence and it was studied on the skin, not injected. GHK-Cu's completed record is a topical study of facial skin quality — NEUVÉ itself sells a topical version and describes it accurately elsewhere on this page. Putting the same molecule in an injection alongside two phase 1 peptides, and claiming collagen and tissue regeneration for the mixture, reaches past every trial behind it.^1,5

Phase 2 only

• NCT00267527 — Phase 2, terminated, n=120. Terminated, not completed — and it studied CJC-1295 in HIV patients with visceral obesity, which is hormone release in a specific clinical population rather than sleep or body composition in healthy adults.

The first sentence is mechanism and is fair; the second is three outcomes and the trial behind them was terminated. The only registry record for CJC-1295 stopped early, enrolled HIV patients with visceral obesity, and measured neither sleep quality nor recovery. Ipamorelin has no registry record of its own here at all, so half the product is undescribed by any trial.⁷

Phase 3 trials

What the trials show for Tesamorelin

• NCT00123253 — Phase 3, completed, n=412. The pivotal trial in HIV patients with excess abdominal fat. The measured outcome was visceral abdominal fat, in that population.
• NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.

This is the most careful tesamorelin claim among the sellers we review. "Reduction of visceral adipose tissue" is exactly what the two phase 3 trials measured, "in specific clinical contexts" concedes that the trial population was narrow, and "not a general weight-loss guarantee" says outright what most sellers of this molecule imply the opposite of. It does not name that context, which was HIV-associated lipodystrophy, so a reader should ask whether they resemble the 675 people the trials enrolled.^8,9

Phase 3 trials

What the trials show for Bremelanotide (PT-141)

• NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder — one of the two trials behind the FDA approval of bremelanotide.
• NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.

"For men and women" is the first thing this card says and the trials enrolled only women — 1,437 premenopausal women with hypoactive sexual desire disorder, across two phase 3 studies that produced an approved product. "Sexual performance" is a third thing again: the RECONNECT outcome was desire and distress, not performance. NEUVÉ never mentions that an approved version of this molecule exists.¹⁰

Phase 3 trials

• NCT02867267 TESTS — Phase 3, completed, n=1,106. Thymosin alpha-1 in SEPSIS — completed phase 3, 1,106 critically ill patients. The strongest evidence this molecule has.

"Ideal for longevity-focused patients" is the exact inversion of this molecule's evidence. As of September 2026, thymosin alpha-1 has 64 randomized-trial records and 64 registered studies, and reading them they are sepsis, hepatitis B, severe pancreatitis, cirrhosis and cancer immunotherapy — the sickest populations in medicine. Nothing has tested it in a well adult optimizing for longevity.¹¹

No trial for this use

As of August 2026, a ClinicalTrials.gov intervention search returns zero records naming Semax and zero naming Selank. PubMed holds 207 records mentioning Semax, of which one carries the randomized-controlled-trial publication type — a 2007 Russian-language paper on motor neuron disease. It holds 68 mentioning Selank, of which two are randomized trials, both in the same Russian journal and both in anxiety disorders.

Three randomized trials exist across both molecules and none studies focus, clarity or cognitive load. Semax's single record is in motor neuron disease; Selank's two are in anxiety disorders, which is closer to "mood" than anything else here but is a clinical diagnosis rather than stress in a high performer. Neither molecule has a registered trial anywhere in the world.¹²

Phase 2 only

• NCT07505745 MOTS-MET — Phase 2, recruiting, n=120. Recruiting, not reporting. No completed human efficacy result exists for a metabolic outcome.

The trial that would answer this is enrolling now. MOTS-MET is recruiting 120 participants for a metabolic outcome, and until it reports there is no human result for metabolic health, energy or exercise performance to point at. "Mitochondrial activation" describes a mechanism observed elsewhere, not an effect measured in a person.¹³

No trial for this use

As of August 2026, a ClinicalTrials.gov intervention search returned zero studies for "Epithalon", zero for "Epitalon" and zero for "Epithalamin" — no registered trial of this molecule exists anywhere, for any indication, under any spelling. In PubMed, a search restricted to the randomized-controlled-trial publication type returns zero records. The randomized literature a looser search surfaces tests EPITHALAMIN, a bovine pineal extract rather than the synthetic tetrapeptide, from a single research group.

"Supports telomerase activity" is the most specific mechanistic claim on this whole menu, and it rests on no registered trial anywhere in the world under any of the molecule's three spellings. The work usually offered in support tests epithalamin, a bovine pineal extract — a different substance. A claim this precise, with a literature this empty, is the sharpest gap on the page.¹⁴

Phase 3 trials

• NCT03323749 — Phase 3, terminated, n=218. Stealth BioTherapeutics, primary mitochondrial myopathy, 218 randomized — TERMINATED rather than completed.
• NCT03098797 — Phase 2/Phase 3, completed, n=12. A twelve-participant crossover trial in a genetic mitochondrial disease.
• NCT02788747 — Phase 2, completed, n=71. Multiple subcutaneous injections of elamipretide, phase 2.

This molecule's trials are in inherited mitochondrial disease — a rare, serious condition — and the largest of them was terminated rather than completed. Twelve participants in one, 71 in another. Nothing there measures cardiovascular health or healthy aging in a well adult, which is what this card sells, and a terminated phase 3 is not a result a claim can rest on.¹⁵